Herzog TJ - Search Results

1

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

Herzog TJ, Scambia G, Kim BG, Lhommé C, Markowska J, Ray-Coquard I, Sehouli J, Colombo N, Shan M, Petrenciuc O, Oza A. Herzog TJ, et al. Gynecol Oncol. 2013 Jul;130(1):25-30. doi: 10.1016/j.ygyno.2013.04.011. Epub 2013 Apr 13. Gynecol Oncol. 2013. PMID: 23591401 Clinical Trial.

2

Topotecan in platinum- and paclitaxel-resistant ovarian cancer.

Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Swisher EM, et al. Among authors: herzog tj. Gynecol Oncol. 1997 Sep;66(3):480-6. doi: 10.1006/gyno.1997.4787. Gynecol Oncol. 1997. PMID: 9299264 Clinical Trial.

3

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog TJ, Rose PG. Markman M, et al. Among authors: herzog tj. Gynecol Oncol. 1999 Dec;75(3):444-6. doi: 10.1006/gyno.1999.5640. Gynecol Oncol. 1999. PMID: 10600304 Clinical Trial.

4

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.

Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Bookman MA, et al. Among authors: herzog tj. Gynecol Oncol. 2000 Jun;77(3):446-9. doi: 10.1006/gyno.2000.5807. Gynecol Oncol. 2000. PMID: 10831357 Clinical Trial.

5

Clinical experience with topotecan in relapsed ovarian cancer.

Herzog TJ. Herzog TJ. Gynecol Oncol. 2003 Sep;90(3 Pt 2):S3-7. doi: 10.1016/s0090-8258(03)00467-0. Gynecol Oncol. 2003. PMID: 13129489 Review.

6

Workshop: options for therapy in ovarian cancer.

Herzog TJ, Holloway RW, Stuart GC. Herzog TJ, et al. Gynecol Oncol. 2003 Sep;90(3 Pt 2):S45-50. doi: 10.1016/s0090-8258(03)00473-6. Gynecol Oncol. 2003. PMID: 13129496 Review.

7

Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J; Gynecologic Oncology Group Study. Look KY, et al. Among authors: herzog tj. Gynecol Oncol. 2004 Jan;92(1):93-100. doi: 10.1016/j.ygyno.2003.09.019. Gynecol Oncol. 2004. PMID: 14751144 Clinical Trial.

8

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

9

The role of maintenance therapy and novel taxanes in ovarian cancer.

Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. Herzog TJ, et al. Gynecol Oncol. 2006 Aug;102(2):218-25. doi: 10.1016/j.ygyno.2005.12.001. Epub 2006 Feb 7. Gynecol Oncol. 2006. PMID: 16460787 Review.

10

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Herzog TJ, et al. Gynecol Oncol. 2006 Nov;103(2):637-41. doi: 10.1016/j.ygyno.2006.04.014. Epub 2006 Jun 15. Gynecol Oncol. 2006. PMID: 16781766 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page